Differential gene expression in models of pituitary prolactin-producing tumoral cells

Hormone Research

Volumn 71, Issue SUPPL. 2, 2009, Pages 88-94

  Giacomini, Damiana ^a,d   Haedo, Mariana ^a   Gerez, Juan ^a   Druker, Jimena ^a   Páez Pereda, Marcelo ^b,c   Labeur, Marta ^b   Stalla, Günter K ^b   Arzt, Eduardo ^a,d  

^a INSTITUTO DE FISIOLOGÍA   (Argentina)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c Affectis Pharmaceutical AG   (Germany)

^d IFYBINE Argentine National Research Council (CONICET)   (Argentina)

Author keywords

BMP 4; Cushing's disease; Oestrogens; Prolactinomas; RSUME; TGF

Indexed keywords

BONE MORPHOGENETIC PROTEIN 4; DOPAMINE 2 RECEPTOR; MESSENGER RNA; PROLACTIN; TRANSFORMING GROWTH FACTOR BETA;

BMP 4 GENE; CARCINOGENESIS; CELL LINE; CELL LINEAGE; CONFERENCE PAPER; GENE EXPRESSION; GENE IDENTIFICATION; HORMONE SYNTHESIS; HUMAN; HYPOPHYSIS; HYPOPHYSIS TUMOR; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROLACTINOMA; PROTEIN FUNCTION; RSUME GENE; SIGNAL TRANSDUCTION; TUMOR CELL; VASCULARIZATION;

ANIMALS; BONE MORPHOGENETIC PROTEIN 4; CELL HYPOXIA; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MICE, KNOCKOUT; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; PROLACTINOMA; RECEPTORS, DOPAMINE D2; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 66749133395     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000192444     Document Type: Conference Paper

References (56)

1. Asa SL, Ezzat S: The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 1998;19:798-827.
2. Ezzat S, Asa SL: Mechanisms of disease: the pathogenesis of pituitary tumors. Nat Clin Pract Endocrinol Metab 2006;2:220-230.
3. Arzt E, Pereda MP, Castro CP, Pagotto U, Renner U, Stalla GK: Pathophysiological role of the cytokine network in the anterior pituitary gland. Front Neuroendocrinol 1999;20: 71-95.
4. Arzt E: gp130 cytokine signaling in the pituitary gland: a paradigm for cytokine-neuroendocrine pathways. J Clin Invest 2001; 108: 1729-1733.
5. Clayton RN, Farrell WE: Pituitary tumour clonality revisited. Front Horm Res 2004;32: 186-204.
6. Alexander JM, Biller BM, Bikkal H, Zervas NT, Arnold A, Klibanski A: Clinically nonfunctioning pituitary tumors are monoclonal in origin. J Clin Invest 1990;86:336-340.
7. Kovacs K, Horvath E, Vidal S: Classification of pituitary adenomas. J Neurooncol 2001; 54:121-127.
8. Yu R, Melmed S: Oncogene activation in pituitary tumors. Brain Path 2001;11:328-341.
9. Melmed S: Update in pituitary disease. J Clin Endocrinol Metab 2008;93:331-338.
10. Castro CP, Giacomini D, Nagashima AC, Onofri C, Graciarena M, Kobayashi K, Paez-Pereda M, Renner U, Stalla GK, Arzt E: Reduced expression of the cytokine transducer gp130 inhibits hormone secretion, cell growth, and tumor development of pituitary lactosomatotrophic GH3 cells. Endocrinology 2003;144:693-700.
11. Carbia-Nagashima A, Gerez J, Perez-Castro C, Paez-Pereda M, Silberstein S, Stalla GK, Holsboer F, Arzt E: RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-lalpha during hypoxia. Cell 2007;131:309-323.
12. Renner U, Lohrer P, Schaaf L, Feirer M, Schmitt K, Onofri C, Arzt E, Stalla GK: Transforming growth factor-beta stimulates vascular endothelial growth factor production by folliculostellate pituitary cells. Endocrinology 2002; 143:3759-3765.
13. Gloddek J, Pagotto U, Paez Pereda M, Arzt E, Stalla GK, Renner U: Pituitary adenylate cy-clase-activating polypeptide, interleukin-6 and glucocorticoids regulate the release of vascular endothelial growth factor in pituitary folliculostellate cells. J Endocrinol 1999;160:483-490.
14. Onofri C, Theodoropoulou M, Losa M, Uhl E, Lange M, Arzt E, Stalla GK, Renner U: Localization of vascular endothelial growth factor (VEGF) receptors in normal and adenomatous pituitaries: detection of a non-en-dothelial function of VEGF in pituitary tumours. J Endocrinol 2006; 191:249-261.
15. Paez-Pereda M, Giacomini D, Refojo D, Nagashima AC, Hopfner U, Grubler Y, Chervin A, Goldberg V, Goya R, Hentges ST, Low M J, Holsboer F, Stalla GK, Arzt E: Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. Proc Natl Acad Sci USA 2003; 100:1034-1039.
16. Schmierer B, Hill CS: TGFbeta-SMAD signal transduction: molecular specificity and functional flexibility. Nat Rev Mol Cell Biol 2007;8:970-982.
17. Massague J: TGF-beta signal transduction. Annu Rev Biochem 1998;67:753-791.
18. Massague J: How cells read TGF-beta signals. Nat Rev Mol Cell Biol 2000;1:169-178.
19. Hentges S, Sarkar DK: Transforming growth factor-beta regulation of estradiol-induced prolactinomas. Front Neuroendocrinol 2001;22:340-363.
20. Shi Y, Massague J: Mechanisms of TGF-beta signalingfrom cell membrane to the nucleus. Cell 2003;113:685-700.
21. Massague J, Chen YG: Controlling TGF-beta signaling. Genes Dev 2000;14:627-644.
22. Bellusci S, Henderson R, Winnier G, Oikawa T, Hogan BL: Evidence from normal expression and targeted misexpression that bone morphogenetic protein (Bmp-4) plays a role in mouse embryonic lung morphogenesis. Development 1996;122:1693-1702.
23. Hogan BL, Blessing M, Winnier GE, Suzuki N, Jones CM: Growth factors in development: the role of TGF-beta related polypeptide signalling molecules in embryogenesis. Dev Suppl 1994:53-60.
24. Winnier G, Blessing M, Labosky PA, Hogan BL: Bone morphogenetic protein-4 is required for mesoderm formation and patterning in the mouse. Genes Dev 1995;9: 2105-2116.
25. Wilson PA, Hemmati-Brivanlou A: Induction of epidermis and inhibition of neural fate by Bmp-4. Nature 1995;376:331-333.
26. Harland RM: Neural induction in Xenopus. Curr Opin Genet Dev 1994;4:543-549.
27. Sasai Y, Lu B, Steinbeisser H, De Robertis EM: Regulation of neural induction by the Chd and Bmp-4 antagonistic patterning signals in Xenopus. Nature 1995;377:757.
28. Lamb TM, Knecht AK, Smith WC, Stachel SE, Economides AN, Stahl N, Yancopolous GD, Harland RM: Neural induction by the secreted polypeptide noggin. Science 1993; 262:713-718.
29. Rossi JM, Dunn NR, Hogan BL, Zaret KS: Distinct mesodermal signals, including BMPs from septum transversum mesenchyme, are required in combination for hepatogenesis from the endoderm. Genes Dev 2001;15:1998-2009.
30. Dudley AT, Lyons KM, Robertson EJ: A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye. Genes Dev 1995;9:2795-2807.
31. Roberts DJ, Johnson RL, Burke AC, Nelson CE, Morgan BA, Tabin C: Sonic hedgehog is an endodermal signal inducing Bmp-4 and Hox genes during induction and regional-ization of the chick hindgut. Development 1995;121:3163-3174.
32. Giacomini D, Paez-Pereda M, Theodoropoulou M, Gerez J, Nagashima AC, Chervin A, Berner S, Labeur M, Refojo D, Renner U, Stalla GK, Arzt E: Bone morphogenetic pro-tein-4 control of pituitary pathophysiology. Front Horm Res 2006;35:22-31.
33. Takeda M, Otsuka F, Suzuki J, Kishida M, Ogura T, Tamiya T, Makino H: Involvement of activin/BMP system in development of human pituitary gonadotropinomas and nonfunctioning adenomas. Biochem Biophys Res Commun 2003;306:812-818.
34. Kawabata M, Imamura T, Miyazono K: Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev 1998; 9:49-61.
35. Chen CR, Kang Y, Massague J: Defective repression of c-myc in breast cancer cells: a loss at the core of the transforming growth factor beta growth arrest program. Proc Natl Acad Sci USA 2001;98:992-999.
36. Yagi K, Furuhashi M, Aoki H, Goto D, Kuwano H, Sugamura K, Miyazono K, Kato M: c-myc is a downstream target of the Smad pathway. J Biol Chem 2002;277:854-861.
37. Nudi M, Ouimette JF, Drouin J: Bone mor-phogenic protein (Smad)-mediated repression of proopiomelanocortin transcription by interference with Pitx/Tpit activity. Mol Endocrinol 2005;19:1329-1342.
38. Morris D, Grossman A: The medical management of Cushing's syndrome. Ann NY Acad Sci 2002;970:119-133.
39. Nieman LK: Medical therapy of Cushing's disease. Pituitary 2002;5:77-82.
40. De Herder WW, Lamberts SW: Octapeptide somatostatin-analogue therapy of Cushing's syndrome. Postgrad Med J 1999;75:65-66.
41. Boscaro M, Barzon L, Fallo F, Sonino N: Cushing's syndrome. Lancet 2001;357:783-791.
42. Merino R, Hurle JM: The molecular basis of retinoid action in tumors. Trends Mol Med 2003;9:509-511.
43. Lotan R: Retinoids in cancer chemopreven-tion. Faseb J 1996;10:1031-1039.
44. Kurie JM: The biologic basis for the use of retinoids in cancer prevention and treatment. Curr Opin Oncol 1999;11:497-502.
45. Kurie JM, Hong WK: Retinoids as antitumor agents: a new age of biological therapy. Cancer J Sci Am 1999;5:150-151.
46. Kang HJ, Song MR, Lee SK, Shin EC, Choi YH, Kim SJ, Lee JW, Lee MO: Retinoic acid and its receptors repress the expression and transactivation functions of Nur77: a possible mechanism for the inhibition of apoptosis by retinoic acid. Exp Cell Res 2000;256: 545-554.
47. Fanjul A, Dawson MI, Hobbs PD, Jong L, Cameron JF, Harlev E, Graupner G, Lu XP, Pfahl M: A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature 1994;372:107-111.
48. Philips A, Lesage S, Gingras R, Maira MH, Gauthier Y, Hugo P, Drouin J: Novel dimeric Nur77 signaling mechanism in endocrine and lymphoid cells. Mol Cell Biol 1997; 17: 5946-5951.
49. Maira M, Martens C, Philips A, Drouin J: Heterodimerization between members of the Nur subfamily of orphan nuclear receptors as a novel mechanism for gene activation. Mol Cell Biol 1999;19:7549-7557.
50. Kovalovsky D, Refojo D, Liberman AC, Hochbaum D, Pereda MP, Coso OA, Stalla GK, Holsboer F, Arzt E: Activation and induction of NUR77/NURR1 in corticotrophs by CRH/cAMP: involvement of calcium, protein kinase A, and MAPK pathways. Mol Endocrinol 2002; 16:1638-1651.
51. Páez-Pereda M, Kovalovsky D, Hopfner U, Theodoropoulou M, Pagotto U, Uhl E, Losa M, Stalla J, Grubler Y, Missale C, Arzt E, Stalla G: Retinoic acid prevents experimental Cushing syndrome. J Clin Invest 2001; 108: 1123-1131.
52. Ling GV, Stabenfeldt GH, Comer KM, Cribble DH, Schechter RD: Canine hyperadreno-corticism: pretreatment clinical and laboratory evaluation of 117 cases. J Am Vet Med Assoc 1979;174:1211-1215.
53. Castillo V, Giacomini D, Paez-Pereda M, Stalla J, Labeur M, Theodoropoulou M, Holsboer F, Grossman AB, Stalla GK, Arzt E: Retinoic acid as a novel medical therapy for Cushing's disease in dogs. Endocrinology 2006;147:4438-4444.
54. Giacomini D, Paez-Pereda M, Theodoropoulou M, Labeur M, Refojo D, Gerez J, Chervin A, Berner S, Losa M, Buchfelder M, Renner U, Stalla GK, Arzt E: Bone morphogenetic protein-4 inhibits corticotroph tumor cells: involvement in the retinoic acid inhibitory action. Endocrinology 2006; 147: 247-256.
55. Yamamoto T, Saatcioglu F, Matsuda T: Crosstalk between bone morphogenic proteins and estrogen receptor signaling. Endocrinology 2002;143:2635-2642.
56. Matsuda T, Yamamoto T, Muraguchi A, Saatcioglu F: Cross-talk between transforming growth factor-beta and estrogen receptor signaling through Smad3. J Biol Chem 2001; 276:42908-42914.